Coverage
-
November 15, 2022
The Federal Circuit on Tuesday handed a win to Abbvie's Pharmacyclics and Johnson & Johnson's Janssen Biotech by saying a generic version of their blockbuster cancer drug Imbruvica infringes their patents, and that those patents aren't invalid.
2 other articles on this case.
View all »